Navigation Links
Pharmatech Oncology to Present at 46th Annual DIA Meeting
Date:6/13/2010

DENVER, June 11 /PRNewswire/ -- On Wednesday June 16, Pharmatech Oncology will chair a session at the 46th Annual DIA Meeting to discuss patient-focused clinical research systems in the age of personalized cancer medicine. Speakers will include Jeffrey Vacirca MD, Director of Clinical Research at North Shore Hematology/Oncology Associates in East Setauket, NY and Matt Baker, President and CEO of Compass IRB in Mesa, AZ.

Dr. Vacirca will discuss the concept of personalized cancer research by reevaluating the site-based research paradigm and the development of a patient focused solution known as Just-In-Time.  Matt Baker will present the development of IRB systems in alignment with the requirements of patient-first research. Furthermore, he will discuss protection of patient rights and regulatory compliance in the modern research setting.  Session chair, Eric Lynam, VP of Business Development at Pharmatech Oncology, comments, "This is a very exciting period in cancer therapeutic research, and the time is at hand to personalize the clinical research process as we focus increasingly on precision cancer medicine.  This session is intended to stimulate discussion and new ideas among pharmaceutical companies, research organizations, physicians, patients, and patient advocates, with a goal toward putting patients first in clinical trials and developing solutions to bring better cancer medicines into the clinic faster."

The Just-In-Time solution is a patient-focused approach that enables research centers to proactively look for clinical trial candidate patients prior to study initiation. Once a potential study patient is identified (using standard-of-care procedures), the site is initiated in an expedited manner. In spite of the challenges involved in clinical trials for patients with rare cancers, Just-In-Time continues to demonstrate that US-based studies can accrue efficiently, while significantly mitigating cost and time related risks. This methodology represents an important step toward a more effective clinical trial system, aligned with the needs of precision cancer treatment. Just-In-Time continues to evolve, setting a new standard for time to first patient enrolled, enrollment rate, and overall patient accrual.

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides oncology-specific Site Management Organization (SMO) and Contract Research Organization (CRO) services to its network of primarily community-based clinics. While experienced in oncology studies, the company's separate Data Management business entity is also capable of providing services for research projects in other disease indications. Pharmatech Oncology's dedication to rapid enrollment and quality data ensures successful development and utilization of therapeutic products among sponsors, investigators, and patients.

About Pharmatech Oncology, Inc.:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides oncology-specific Site Management Organization (SMO) and Contract Research Organization (CRO) services to its network of primarily community-based clinics. While experienced in oncology studies, the company's separate Data Management business entity is also capable of providing services for research projects in other disease indications . Pharmatech Oncology's dedication to rapid enrollment and quality data ensures successful development and utilization of therapeutic products among sponsors, investigators, and patients.

For more information about Pharmatech, please visit www.pharmatechoncology.com.

For more information about Compass IRB, please visit www.compassirb.com

Key words: Cancer, clinical trials, contract research, oncology, patients, research, site management


'/>"/>
SOURCE Pharmatech Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
2. WuXi PharmaTech Announces Second Quarter 2007 Results
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
9. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
10. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
11. WuXi PharmaTech Completes Acquisition of AppTec
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... Disappearing forests and ... lives of over 5.5 million people each year. Especially those living in larger cities ... Treepex - based in one of the most pollution-affected countries globally - decided to ...
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon ... awards honoring scientists who have made outstanding contributions to analytical chemistry ... Pittcon 2018, the world’s leading conference and exposition for laboratory science, which will ...
(Date:10/9/2017)... Antonio, Texas (PRWEB) , ... ... ... new study published on October 5, 2017, in the medical journal, Epilepsia, ... equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic seizures ...
Breaking Biology Technology:
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
Breaking Biology News(10 mins):